Eduard Mension, Inmaculada Alonso, Marta Tortajada, Isabel Matas, Sílvia Gómez, Laura Ribera, Cristina Ros, Sònia Anglès-Acedo, Camil Castelo-Branco
New therapeutic options are being considered to treat genitourinary syndrome of menopause (GSM), such as vaginal laser, ospemifene, or prasterone, but there is no explicit agreement in the scientific community for its use. Some concerns have arisen on how to evaluate the improvement of GSM symptoms. In 2003, the FDA suggested possible end points for this purpose: change in severity of symptoms, change in vaginal pH, and change in vaginal maturation index (VMI). Contrarily, the most common assessment tools used to quantify severity and improvement of GSM nowadays are the visual analog scale of GSM symptoms, the vaginal health index, and the female sexual function index...
April 2021: Journal of Mid-life Health